Aclarion to Showcase Nociscan at LD Micro Main Event

Event summary

Aclarion (NASDAQ: ACON) will present at the 20th Annual LD Micro Main Event on October 20, 2026, at 11:30 AM PT.
CEO Brent Ness will represent the company at the event held in Los Angeles.
The event features over 100 public companies presenting to investors.
Aclarion's Nociscan platform aims to optimize clinical treatments for chronic low back pain.

The big picture

Aclarion's participation in the LD Micro Main Event underscores its focus on engaging with micro-cap investors to drive awareness of its Nociscan technology. The event provides a platform for the company to showcase its innovative approach to diagnosing chronic low back pain, a market with significant unmet needs. As the healthcare technology sector continues to evolve, Aclarion's ability to differentiate its product through proprietary algorithms and biomarkers will be crucial for its long-term success.

What we're watching

Technology Validation: How Aclarion's presentation will position Nociscan in the competitive landscape of diagnostic tools for chronic low back pain.
Investor Sentiment: Whether the event will attract significant investor interest, potentially impacting Aclarion's market valuation.
Commercialization Strategy: The pace at which Aclarion can scale its SaaS platform and expand into other clinical applications beyond low back pain.